{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:38:38Z","timestamp":1793219918120,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.clgc.2017.09.006","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T14:45:18Z","timestamp":1506350718000},"page":"e297-e305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Factors Influencing Overall Survival for Patients With Metastatic Clear-Cell Renal-Cell Carcinoma in Daily Practice"],"prefix":"10.1016","volume":"16","author":[{"given":"Antoine","family":"Thiery-Vuillemin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiphaine","family":"Cholley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Calcagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2492-4836","authenticated-orcid":false,"given":"Marion","family":"Hugues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Maurina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Limat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Nguyen Tan Hon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamadi","family":"Almotlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Mouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Nerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2017.09.006_bib1","unstructured":"National Cancer Institute. Cancer stat facts: kidney and renal pelvis cancer\u2014the Surveillance, Epidemiology, and End Results (SEER) database. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html. Accessed: February 15,\u00a02017."},{"key":"10.1016\/j.clgc.2017.09.006_bib2","unstructured":"American Society Cancer. Kidney cancer (adult)\u2014renal cell carcinoma. Available at: https:\/\/www.cancer.org\/cancer\/kidney-cancer\/. Accessed: January 3,\u00a02017."},{"key":"10.1016\/j.clgc.2017.09.006_bib3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2017.09.006_bib4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ncpuro1121","article-title":"Importance of surgical margins in the management of renal cell carcinoma","volume":"5","author":"Lam","year":"2008","journal-title":"Nat Clin Pract Urol"},{"key":"10.1016\/j.clgc.2017.09.006_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.critrevonc.2008.08.006","article-title":"Renal cell carcinoma: risk assessment and prognostic factors for newly diagnosed patients","volume":"70","author":"Downs","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2017.09.006_bib6","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.eururo.2009.06.036","article-title":"Reassessing the current UICC\/AJCC TNM staging for renal cell carcinoma","volume":"56","author":"Moch","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2017.09.006_bib7","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology\u2014kidney cancer, version 1, 2013. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed: September 24, 2017."},{"key":"10.1016\/j.clgc.2017.09.006_bib8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0094-0143(03)00056-9","article-title":"Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease","volume":"30","author":"Janzen","year":"2003","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.clgc.2017.09.006_bib9","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","article-title":"Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer","volume":"345","author":"Flanigan","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2017.09.006_bib10","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","article-title":"Radical nephrectomy plus interferon-alfa\u2013based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial","volume":"358","author":"Mickisch","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2017.09.006_bib11","first-page":"860","article-title":"Von Hippel\u2013Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma","volume":"180","author":"Choueiri","year":"2008","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2017.09.006_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1634\/theoncologist.10-3-191","article-title":"VEGF-targeted therapy in metastatic renal cell carcinoma","volume":"10","author":"Rini","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2017.09.006_bib13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1517\/14740330903530663","article-title":"Safety profile of new anticancer drugs","volume":"9","author":"Mansi","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clgc.2017.09.006_bib14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nm1337","article-title":"Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer","volume":"12","author":"Thomas","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2017.09.006_bib15","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2017.09.006_bib16","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/j.clgc.2016.08.022","article-title":"Survival of patients with advanced or metastatic renal cell carcinoma in routine practice differs from that in clinical trials\u2014analyses from the German Clinical RCC Registry","volume":"15","author":"Marschner","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2017.09.006_bib17","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","article-title":"Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma","volume":"22","author":"Motzer","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2017.09.006_bib18","doi-asserted-by":"crossref","first-page":"e63341","DOI":"10.1371\/journal.pone.0063341","article-title":"Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era","volume":"8","author":"Pal","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2017.09.006_bib19","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2017.09.006_bib20","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdv601","article-title":"Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study","volume":"27","author":"P\u00e9rez-Valderrama","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2017.09.006_bib21","unstructured":"Ljungberg B, Albiges L, Bensalah K, Bex A, Giles RH. European Association of Urology Guideline 2017\u2014renal cell cancer. Available at: http:\/\/uroweb.org\/guideline\/renal-cell-carcinoma\/. Accessed: September 6,\u00a02017."},{"key":"10.1016\/j.clgc.2017.09.006_bib22","doi-asserted-by":"crossref","first-page":"167.e17","DOI":"10.1016\/j.urolonc.2015.10.015","article-title":"Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era","volume":"34","author":"Gravis","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2017.09.006_bib23","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.2005.05.179","article-title":"Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma","volume":"23","author":"Mekhail","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2017.09.006_bib24","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2016.05.049","article-title":"Third-line targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"71","author":"Wells","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2017.09.006_bib25","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/j.ejca.2013.02.003","article-title":"Second line treatment of metastatic renal cell carcinoma: the Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients","volume":"49","author":"Levy","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2017.09.006_bib26","first-page":"44","article-title":"Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"197","author":"Zaid","year":"2017","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2017.09.006_bib27","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2014.11.054","article-title":"Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies","volume":"68","author":"Kroeger","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2017.09.006_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2017.09.006_bib29","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2017.09.006_bib30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2017.09.006_bib31","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1038\/bjc.2014.244","article-title":"Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial","volume":"110","author":"Escudier","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2017.09.006_bib32","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2017.09.006_bib33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clgc.2014.09.005","article-title":"Efficacy and safety of sequential use of everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab with or without interferon therapy: results from the European AVATOR study","volume":"13","author":"Thiery-Vuillemin","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2017.09.006_bib34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.clgc.2017.01.005","article-title":"Discontinuing VEGF-targeted therapy for progression versus toxicity affects outcomes of second-line therapies in metastatic renal cell carcinoma","volume":"15","author":"De Velasco","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2017.09.006_bib35","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2017.09.006_bib36","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2017.09.006_bib37","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767317302811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767317302811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:29:08Z","timestamp":1761564548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767317302811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1558767317302811"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2017.09.006","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors Influencing Overall Survival for Patients With Metastatic Clear-Cell Renal-Cell Carcinoma in Daily Practice","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2017.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}